Clarity Pharmaceuticals Ltd. · ASX:CU6
Clarity Pharmaceuticals — Shareholder Meeting (November 2021)
16 slides from Clarity Pharmaceuticals's shareholder meeting presentation, Nov 25, 2021
Slide 1: Managing Director's Presentation
Managing Director’s Presentation Annual General Meeting 25 November 2021 Dr Colin Biggin
Slide 2: Disclaimer
Disclaimer Introduction No representation, warranty or assurance (express or implied) is given or made in relation to any forward- This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the looking statement by any person (including any of the Limited Partie
Slide 3: Clarity's clinical development pipeline
Clarity’s clinical development pipeline Clarity’s products are progressing through Phase I and Phase II clinical trials with two open IND applications that received clearance to proceed to clinical trials from the FDA, two RPDDs and two ODDs from the FDA Robust clinical trial strategy Developing p
Slide 4: US prostate cancer in numbers
US prostate cancer in numbers 1:8 US men will develop 2nd prostate cancer in their lifetime most common cancer in US men 34,130 men will die annually of >3.1M prostate cancer in the US living with prostate cancer today in US 248,530 new cases of >200,000 prostate cancer in Currently investigated in
Slide 5: SAR-bisPSMA: Pre-clinical data
SAR-bisPSMA: Pre-clinical data SAR-bisPSMA has ideal product characteristics for a radiopharmaceutical ‘Bis-PSMA’ High uptake and retention in tumour The term Bis is used to denote the 120 Preclinical biodistribution presence of two 80 study demonstrating high Rapid kidney clearance of identical but
Slide 6: SAR-bisPSMA: Current clinical trials
SAR-bisPSMA: Current clinical trials SECuRE: Systemic Copper theranostics in PROPELLER: PET Imaging of Participants With prostate cancer (NCT04868604) Confirmed Prostate Cancer (NCT04839367) A Phase I/IIa study of 64Cu SAR-bisPSMA and 67Cu SAR- A Phase I multi-centre, blinded review, dose ranging, b
Slide 7: SAR-bisPSMA mCRPC therapy
SAR-bisPSMA mCRPC therapy Preliminary imaging results from the dosimetry phase of the theranostic SECuRE clinical trial PET scans in a patient with metastatic castrate-resistant prostate 64Cu SAR- Comparison of 1h 64Cu SAR- cancer imaged over multiple timepoints between 1 and 72 hours post bisPSMA P
Slide 8: SAR-Bombesin in prostate cancer
SAR-Bombesin in prostate cancer Detection of PSMA-negative prostate cancer (PC) 68Ga PSMA-11 (top) images of a PSMA-negative 68Ga PSMA-11 (top) images of a PSMA- patient with clinical signs of PC (a rising PSA score of negative patient with history of PC (a rising PSA • ~10% of prostate cancer patie
Slide 9: SAR-Bombesin: A pan-cancer target
SAR-Bombesin: A pan-cancer target SAR-Bombesin is a highly targeted pan-cancer theranostic radiopharmaceutical being developed for identifying and selecting patients for subsequent treatment of their cancers that express gastrin releasing peptide receptor (GRPr) 64Cu SAR-Bombesin in hormone positive
Slide 10: SAR-Bombesin in metastatic breast cancer
SAR-Bombesin in metastatic breast cancer C-BOBCAT: Recruitment closed First-in-human pilot trial assessment of the C-BOBCAT: One hour post 64Cu-SAR-Bombesin administration in a breast diagnostic value of 64Cu SAR-Bombesin PET/CT cancer patient imaging for staging of hormone positive breast 64Cu SAR-
Slide 11: SARTATE – next generation theranostic
SARTATE™ – next generation theranostic SARTATE™ is a highly targeted theranostic radiopharmaceutical which is being developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2 (SSTR2) High Accuracy Target benefits High Precision • Targets tumours that exp
Slide 12: SARTATE: Clinical trials
SARTATE™: Clinical trials SARTATE™ CL04: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to DISCO: Diagnostic Imaging Study of Copper-64 Pediatric Patients With High-Risk, Relapsed, SARTATE using PET on patients with known or Refractory Neuroblastoma (NCT 04023331) suspected NETs (N
Slide 13: Clinical development pipeline - 12 month progress
Clinical development pipeline - 12 month progress Clarity is rapidly progressing its pipeline of TCT products through clinical development as the Company anticipates the achievement of significant milestones in the next year *Note clinical development pipeline is indicative only, subject to review.
Slide 14: Slide from Clarity AGM 2020
Slide from Clarity AGM 2020 Clarity delivered on all our goals for 2021 from the last AGM 14
Slide 15: Inflection points to Q4 2022
Inflection points to Q4 2022 >50% recruitment Recruitment FPFV BBN US DISCO complete Dx US manufacture PROPELLER expansion Advance Advance Advance 1st PSMA Tx to Cohort 2: to Cohort 3: to Cohort 4: NB Tx PSMA Tx PSMA Tx Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Recruitment Dosimetry Open IND Open IND
Slide 16: Contact details
Contact details Dr Alan Taylor Dr Colin Biggin Executive Chairman Managing Director E: alan.taylor@claritypharm.com E: colin.biggin@claritypharm.com Alan has been instrumental in the growth of Clarity Colin has over 15 years of radiopharmaceutical over the last seven years, leading the Company devel
Clarity Pharmaceuticals — Shareholder Meeting (November 2021) on 6ix